Åpne denne publikasjonen i ny fane eller vindu >>Vise andre…
2020 (engelsk)Inngår i: Scientific Reports, E-ISSN 2045-2322, Vol. 10, nr 1, artikkel-id 8029Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]
Endomyocardial biopsy is a valuable tool in cardiac diagnostics but is limited by low diagnostic yield and significant complication risks. Meanwhile, recent developments in transcriptomic and proteomic technologies promise a wealth of biological data from minimal tissue samples. To take advantage of the minimal tissue amount needed for molecular analyses, we have developed a sub-millimeter endovascular biopsy device, considerably smaller than current clinical equipment, and devised a low-input RNA-sequencing protocol for analyzing small tissue samples. In in vivo evaluation in swine, 81% of biopsy attempts (n=157) were successful. High quality RNA-sequencing data was generated from 91% of the sequenced cardiac micro-biopsy samples (n=32). Gene expression signatures of samples taken with the novel device were comparable with a conventional device. No major complications were detected either during procedures or during 7 days' follow-up, despite acquiring a relatively large number of biopsies (median 30) in each animal. In conclusion, the novel device coupled with RNA-sequencing provides a feasible method to obtain molecular data from the myocardium. The method is less traumatic and has a higher flexibility compared to conventional methods, enabling safer and more targeted sampling from different parts of the myocardium.
sted, utgiver, år, opplag, sider
Springer Nature, 2020
HSV kategori
Identifikatorer
urn:nbn:se:kth:diva-281166 (URN)10.1038/s41598-020-64900-w (DOI)000562205900004 ()32415191 (PubMedID)2-s2.0-85084785903 (Scopus ID)
Merknad
QC 20201015
2020-10-152020-10-152023-08-09bibliografisk kontrollert